Research goal
Covers compounds investigated for adipose tissue reduction, appetite regulation, metabolic rate modulation, and body composition improvement in research settings.
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| Retatrutide | GLP-1/GIP/Glucagon triple agonist | Triple incretin receptor agonism; appetite suppression + energy expenditure | Fat loss, body recomposition | View profile → |
| Tirzepatide | GLP-1/GIP dual agonist | Dual incretin receptor agonism; enhanced insulin sensitivity | Weight reduction, metabolic improvement | View profile → |
| Semaglutide | GLP-1 agonist | GLP-1 receptor agonism; slows gastric emptying, reduces appetite | Appetite control, sustained weight loss | View profile → |
| AOD-9604 | GH fragment | Stimulates fat metabolism via β3-adrenergic receptors; does not affect IGF-1 | Targeted fat loss without GH side effects | View profile → |
| Fragment 176-191 | GH fragment | C-terminal GH fragment; lipolytic activity without growth-promoting effects | Localised fat breakdown in research | View profile → |
The GLP-1, GIP, and glucagon receptor pathways represent three distinct but complementary axes of metabolic regulation. GLP-1 receptor agonism slows gastric emptying, suppresses appetite via hypothalamic signalling, and augments glucose-dependent insulin secretion. GIP receptor co-agonism adds adipose tissue insulin sensitivity and may potentiate GLP-1's insulinotropic effects. Glucagon receptor agonism, the third axis incorporated in compounds such as retatrutide, independently increases resting energy expenditure by driving hepatic fat oxidation and thermogenesis. Research into triple agonism suggests that energy expenditure increases beyond what appetite suppression alone can account for, making this pathway of particular interest in studies of severe obesity and metabolic syndrome.
Insulin sensitivity is a central determinant of the body's capacity to utilise fat as a fuel substrate. When peripheral tissues respond poorly to insulin, elevated circulating insulin levels suppress lipolysis, effectively locking fatty acids within adipose stores and reducing fat oxidation in muscle. Compounds that improve insulin receptor signalling — through incretin-mediated mechanisms or independently — have been investigated for their ability to restore this partitioning, shifting substrate utilisation toward fat. Research has investigated tirzepatide in particular for its role in improving hepatic and peripheral insulin sensitivity, with downstream effects on lipid profiles and adipose volume reduction observed in clinical trial populations.
Growth hormone fragments represent a structurally distinct approach to lipolysis research. Full-length growth hormone exerts both lipolytic effects and growth-promoting effects mediated primarily through IGF-1 signalling. Researchers identified that the C-terminal region of the GH molecule — specifically residues 176–191 — appears to retain lipolytic activity while lacking affinity for the IGF-1 pathway. AOD-9604, a synthetic analogue of this fragment with a stabilising modification, has been investigated for its potential to stimulate β3-adrenergic receptor activity, promoting adipocyte lipolysis without the anabolic side effects associated with exogenous GH. This mechanistic separation has made GH fragments an area of interest for research focused specifically on fat mass reduction rather than overall anabolism.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Research has investigated retatrutide for its potential role in producing substantial reductions in body weight and adipose mass, with phase 2 trial data suggesting outcomes at the higher end of what incretin-based compounds have demonstrated. The glucagon receptor component distinguishes it from dual agonists by independently elevating energy expenditure, a mechanism that may explain the more pronounced body weight reductions observed in research. Commonly reported doses range from 2 mg to 12 mg weekly in research escalation protocols. Anecdotal reports suggest improvement in appetite regulation begins early in the dose escalation phase.
Tirzepatide acts as a dual agonist at GLP-1 and GIP receptors, a combination that clinical research has investigated for its role in improving both glycaemic control and body weight in populations with type 2 diabetes and obesity. GIP receptor agonism differentiates tirzepatide from earlier GLP-1-only compounds, with research suggesting that co-activation of the GIP pathway amplifies insulin sensitivity in both adipose and hepatic tissue. Research has investigated tirzepatide for its potential role in reducing visceral adipose tissue volume, with favourable changes in lipid panels and liver fat content reported in trial populations. Commonly reported research doses range from 2.5 mg to 15 mg weekly administered subcutaneously, typically escalated over several months.
Semaglutide is a GLP-1 receptor agonist with a prolonged half-life achieved through albumin-binding fatty acid modification, enabling once-weekly dosing. Research has investigated semaglutide for its potential role in appetite reduction, slowed gastric emptying, and sustained weight loss over extended timeframes. The STEP trial programme provided substantial data on semaglutide's effects on body weight in non-diabetic populations, establishing it as a reference point in pharmacological weight loss research. Commonly reported doses range from 0.25 mg weekly as a starting point, escalating to 2.4 mg weekly in weight management research contexts. Reported side effects in research and anecdotal accounts include nausea, delayed gastric emptying, and gastrointestinal discomfort, particularly during dose escalation.
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, with a disulphide bond modification for stability. Research has investigated AOD-9604 for its potential role in stimulating lipolysis via β3-adrenergic receptor pathways, with preclinical data suggesting adipocyte fat mobilisation without detectable IGF-1 elevation or anabolic activity. This mechanistic profile makes it of interest to researchers seeking fat-specific effects without the growth-promoting consequences of full GH. Commonly reported doses in research settings range from 250 mcg to 500 mcg per administration. Anecdotal reports suggest improvement in body composition when combined with caloric restriction, though robust human trial data remain limited.
Fragment 176-191 refers to the 176th through 191st amino acid sequence of the human growth hormone molecule, isolated and studied for its lipolytic properties independent of the rest of the GH structure. Research has investigated Fragment 176-191 for its potential role in stimulating fat oxidation in adipose tissue without activating the IGF-1 axis or promoting tissue growth. Preclinical models have demonstrated reductions in body fat in obese rodent subjects, though translation to human populations has been less extensively studied. Commonly reported doses in anecdotal research contexts range from 250 mcg to 500 mcg per day, administered subcutaneously. The compound is often discussed alongside AOD-9604 as a structurally related comparator in GH fragment research.
No established stack protocols documented for this goal — individual protocols are typically run independently.
What is the mechanistic difference between GLP-1 agonists and GH fragments for fat loss?
GLP-1 agonists such as semaglutide and tirzepatide primarily reduce fat mass by suppressing appetite through central nervous system signalling and slowing gastric emptying, creating a caloric deficit. They also improve insulin sensitivity, which indirectly supports fat utilisation. GH fragments such as AOD-9604 and Fragment 176-191 operate through a fundamentally different mechanism, directly stimulating lipolysis within adipocytes via adrenergic pathways without requiring a caloric deficit to initiate fat mobilisation. Research has investigated each class for distinct downstream effects, and the two pathways are not mechanistically redundant.
How long do research protocols for these compounds typically run?
Clinical trials for GLP-1 and GIP receptor agonists such as semaglutide and tirzepatide have commonly run for 68 to 72 weeks, reflecting the gradual nature of body weight reduction at therapeutic doses and the need for a dose escalation period. GH fragment protocols in anecdotal research contexts are commonly reported at 8 to 16 weeks, though this is not based on established clinical trial data given the more limited human research base for those compounds. Duration in research settings is typically dictated by the outcome being measured and the rate of physiological change.
Is appetite suppression or metabolic rate increase the primary driver of fat loss with these compounds?
For GLP-1 agonists, appetite suppression — and the resulting caloric deficit — is considered the dominant mechanism in human research, with improvements in insulin sensitivity playing a supporting role. For triple agonists such as retatrutide, the addition of glucagon receptor agonism introduces a meaningful energy expenditure component, making metabolic rate elevation more relevant. GH fragments, conversely, are proposed to act primarily on lipolysis directly rather than appetite. Research has not definitively established a single dominant driver across the class, and the relative contribution of each mechanism varies considerably by compound.
Have GLP-1 agonists and GH fragments been studied in combination?
Formal clinical research combining GLP-1 receptor agonists with GH fragments such as AOD-9604 or Fragment 176-191 is limited. The mechanistic rationale for combination — appetite suppression and insulin sensitisation from one class, direct lipolysis from the other — has been discussed in preclinical and anecdotal research contexts, but no peer-reviewed human trial data exist to characterise the interaction, additive effects, or safety profile of such combinations. Research in this area remains exploratory.